Quick Answer
TScan Therapeutics, Inc. reported R&D Expense of $114.15 million for fiscal year 2025.
TScan Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $114.15M | +6.3% |
| 2024 | $107.35M | +21.8% |
| 2023 | $88.15M | +47.4% |
| 2022 | $59.82M | +33.1% |
| 2021 | $44.95M | +118.5% |
| 2020 | $20.58M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.69M | +20.7% | -2.9% |
| June 30, 2025 | $32.63M | +21.4% | +9.6% |
| March 31, 2025 | $29.79M | +19.8% | +13.4% |
| September 30, 2024 | $26.26M | +15.5% | -2.3% |
| June 30, 2024 | $26.88M | +26.6% | +8.1% |
| March 31, 2024 | $24.86M | +14.1% | +9.3% |
| September 30, 2023 | $22.74M | +51.3% | +7.1% |
| June 30, 2023 | $21.23M | +46.5% | -2.5% |
- TScan Therapeutics, Inc. showed an increase of +6.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, TScan Therapeutics, Inc.’s r&d expense has grown by 454.7% (from $20.58 million to $114.15 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: